Literature DB >> 20724911

Hydralazine-induced pulmonary-renal syndrome: a case report.

Ankur Kalra1, Naoto Yokogawa, Haroon Raja, Chandrasekar Palaniswamy, Priyank Desai, Sergio L Zanotti-Cavazzoni, Sri-Sujanthy Rajaram.   

Abstract

Drug-induced lupus erythematosus differs in its manifestation from drug-induced vasculitis. The former is associated with characteristic symptoms that improve following discontinuation, whereas the latter is predominantly an antineutrophil cytoplasmic antibody (ANCA) positive small vessel vasculitis involving the kidneys, skin, and lungs. We present a case of advanced disease in an elderly Caucasian woman requiring corticosteroids, and immunosuppressive therapy, who was on hydralazine for >2 years.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 20724911     DOI: 10.1097/MJT.0b013e3181ed838c

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

Review 1.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

2.  Hydralazine-Induced Isolated Lupus Nephritis.

Authors:  Naseer Khan; Ronald Reichel; Ayesha Khurshid; Katie Tso; Joan Broussard; Amrika Dass
Journal:  Ochsner J       Date:  2020

Review 3.  Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.

Authors:  Rafael G Grau
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.